[1]关李稳,刘真义,周真真,等.溃疡性结肠炎患者血清LncRNA TUG1 和miR-142-5p 表达与疾病活动度及预后的关系[J].现代检验医学杂志,2023,38(05):70-74+79.[doi:10.3969/j.issn.1671-7414.2023.05.013]
　GUAN Liwen,LIU Zhenyi,ZHOU Zhenzhen,et al.Relationship between Serum LncRNA TUG1 and miR-142-5p Expression and Disease Activity and Prognosis in Patients with Ulcerative Colitis[J].Journal of Modern Laboratory Medicine,2023,38(05):70-74+79.[doi:10.3969/j.issn.1671-7414.2023.05.013]
点击复制

溃疡性结肠炎患者血清LncRNA TUG1 和miR-142-5p 表达与疾病活动度及预后的关系()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第38卷
期数:
2023年05期
页码:
70-74+79
栏目:
论著
出版日期:
2023-09-15

文章信息/Info

Title:
Relationship between Serum LncRNA TUG1 and miR-142-5p Expression and Disease Activity and Prognosis in Patients with Ulcerative Colitis
文章编号:
1671-7414（2023）05-070-06
作者:
关李稳; 刘真义; 周真真; 王力雅; 阚 娜
（海南省第三人民医院消化内科，海南三亚 572000）
Author(s):
GUAN Liwen;  LIU Zhenyi;  ZHOU Zhenzhen;  WANG Liya;  KAN Na
（Department of Gastroenterology, the Third People’s Hospital of Hainan, Hainan Sanya 572000，China）
关键词:
溃疡性结肠炎; 长链非编码核糖核酸牛磺酸上调基因1; 微小核糖核酸-142-5p
分类号:
R574.62；R392.11
DOI:
10.3969/j.issn.1671-7414.2023.05.013
文献标志码:
A
摘要:
目的 分析溃疡性结肠炎（ulcerative colitis，UC）患者血清长链非编码核糖核酸牛磺酸上调基因1（long noncodingRNA taurine upregulated gene 1，LncRNA TUG1）、微小核糖核酸（microRNA，miR）-142-5p 表达水平与UC 疾病活动度及预后的关系。方法 选取2017 年1 月～ 2020 年5 月期间海南省第三人民医院收治的UC 患者108 例为UC组，根据改良Mayo 评分将UC 患者分为缓解期组（Mayo 评分在2 分及以下而且无单个分项评分在1 分，n=42）、轻度活动组（3 分≤ Mayo 评分≤ 5 分，n=21）、中度活动组（6 分≤ Mayo 评分≤ 10 分，n=24）和重度活动组（11 分≤ Mayo 评分≤ 12 分，n=21）。对UC 患者随访2 年，记录其复发情况。另选取同期体检健康者108 例为健康组。实时荧光定量PCR 法测定血清LncRNA TUG1 和miR-142-5p 表达水平；比较UC 组和健康组、不同疾病活动度UC 患者、不同预后UC 患者血清LncRNA TUG1 和miR-142-5p 表达水平；分析UC 患者血清LncRNA TUG1 表达水平与miR-142-5p 的相关性及影响UC 患者预后的因素。结果 与健康组相比，UC 组患者血清LncRNA TUG1 表达水平（0.45±0.15 vs 1.04±0.35）降低，miR-142-5p 表达水平（1.76±0.32 vs 1.01±0.18）升高，差异均有统计学意义（t=16.102，21.229，均P ＜ 0.05）。UC 患者血清LncRNA TUG1 表达水平与miR-142-5p 呈负相关（r=-0.558，P ＜ 0.05）；缓解期组、轻度活动组、中度活动组和重度活动组血清LncRNA TUG1 表达水平依次降低（0.68±0.23，0.48±0.16，0.29±0.09，0.13±0.05），miR-142-5p 表达水平依次升高（1.48±0.27，1.55±0.28，1.97±0.36，2.30±0.42），差异有统计学意义（F=59.475，35.716，均P ＜ 0.05）。108 例UC 患者随访2 年，复发51 例（复发组），未复发57 例（未复发组），与未复发组相比，复发组UC 患者血清LncRNA TUG1 表达水平（0.38±0.13 vs 0.51±0.17）降低，miR-142-5p 表达水平（1.93±0.35 vs 1.61±0.29）和有肠外表现患者占比（21/30 vs 9/48）升高，差异均有统计学意义（t=4.424~8.647，均P ＜0.05）；肠外表现（OR=2.366，95%CI=1.558～ 3.592，P＜ 0.001）和miR-142-5p（OR=2.563，95%CI=1.649～ 3.984，P＜ 0.001）是影响UC 患者预后的危险因素，而LncRNA TUG1（OR=0.680，95%CI=0.557 ～ 0.830，P ＜ 0.001）是影响UC 患者预后的保护因素。结论 UC 患者血清LncRNA TUG1 呈低表达而miR-142-5p 呈高表达，均与UC 疾病活动度、预后密切相关，测定二者水平有助于临床评估UC 患者病情及预后。
Abstract:
108 UC patients accepted by the Third People’s Hospital of Hainan Province during January 2017 to May 2020 were gathered as the UC group. According to the modified Mayo score, patients with UC were divided into remission group (Mayo score was 2 or less and no single sub-score was more than 1, n=42) , mild activity group (3 ≤ Mayo score ≤ 5, n=21), moderate activity group (6 ≤ Mayo score ≤ 10, n=24) and mild activity group (11 ≤ Mayo score ≤ 12, n=21). The patients with UC were followed up for 2 years and the recurrence was recorded. In addition, 108 healthy people during physical examination were selected as the healthy group. Real-time fluorescent quantitative PCR method was used to determine the expression levels of serum LncRNA TUG1 and miR-142-5p. The expression levels of LncRNA TUG1 and miR-142-5p in serum were compared between UC group and healthy group, UC patients with different disease activity, and UC patients with different prognosis. Analyzed the correlation between the expression level of serum LncRNA TUG1 and miR-142-5p in UC patients and the prognostic factors of UC patients. Results Compared with the healthy group, the expression level of serum LncRNA TUG1 (0.45± 0.15 vs 1.04±0.35) in UC group was decreased, and the expression level of miR-142-5p (1.76±0.32 vs 1.01±0.18) was increased, the differences were statistically significant (t=16.102, 21.229, all P<0.05). The expression level of serum LncRNA TUG1 in UC patients was negatively correlated with miR-142-5p (r=-0.558, P<0.05). The expression level of serum LncRNA TUG1 (0.68±0.23, 0.48±0.16, 0.29±0.09, 0.13±0.05) in remission group, mild activity group, moderate activity group and severe activity group were successively decreased, the expression level of miR-142-5p (1.48±0.27, 1.55±0.28, 1.97±0.36, 2.30±0.42) were successively increased, and the differences were statistically significant (F=59.475, 35.716, all P<0.05). 108 UC patients were followed up for 2 years, 51 patients had recurrence (recurrence group) and 57 patients did not relapse (nonrecurrence group). Compared with the non-recurrence group, the expression level of serum LncRNA TUG1 (0.38±0.13 vs 0.51±0.17) in UC patients in the recurrence group was decreased, the expression level of miR-142-5p (1.93±0.35 vs 1.61±0.29) and the proportion of patients with parenteral manifestations (21/30 vs 9/48) were increased, and the differences were statistically significant (t=4.424 ～ 8.647, all P<0.05). Parenteral manifestations (OR=2.366, 95%CI：1.558 ～ 3.592, P<0.001) and miR-142-5p (OR=2.563, 95%CI：1.649 ～ 3.984, P<0.001) were risk factors for the prognosis of UC patients, and LncRNA TUG1 (OR=0.680, 95%CI：0.557 ～ 0.830, P<0.001) was a protective factor for the prognosis of UC patients. Conclusion The low expression of LncRNA TUG1 and the high expression of miR-142-5p in the serum of UC patients, were closely related to the disease activity and prognosis of UC, the determination of the two levels is helpful for clinical evaluation of the disease and prognosis of UC patients.

参考文献/References:

[1] ZHANG Zhaohua, LIU Rong, NANA D U, et al. Efficacy of Sishen Wan on dinitrobenzene sulfonic acid-induced ulcerative colitis and its effect on toll-like receptor 2/interleukin-1 receptor-associated kinase-4/nuclear factor-κB signal pathway[J]. J Tradit Chin Med, 2022, 42(4):565-575.
[2] 杨思贤, 慕奕彤, 牛福玉. 粪便S100A12，钙卫蛋白和乳铁蛋白对溃疡性结肠炎患者疾病活动度和黏膜愈合评估价值分析[J]. 现代检验医学杂志, 2022,37(3):172-176. YANG Sixian, MU Yitong, NIU Fuyu. Evaluation value of stool s100a12, fecal calprotectin and lactoferrin for disease activity and mucosal healing in patients with ulcerative colitis[J]. Journal of Modern Laboratory Medicine, 2022, 37(3):172-176.
[3] DU L, HA C. Epidemiology and pathogenesis of ulcerative colitis[J]. Gastroenterol Clin North Am, 2020, 49(4):643-654.
[4] LI Hui, XUAN Ji, ZHANG Wei, et al. Long noncoding RNA SNHG5 regulates ulcerative colitis via microRNA-375 / Janus kinase-2 axis[J]. Bioengineered, 2021, 12(1):4150-4158.
[5] TIAN Yuxi, WANG Ying, LI Fujun, et al. LncRNA TUG1 regulates the balance of HuR and miR-29b-3p and inhibits intestinal epithelial cell apoptosis in a mouse model of ulcerative colitis[J]. Hum Cell, 2018, 11(12): 5735-5744.
[6] HAN Jing, LI Yawei, ZHANG Hong, et al. MicroRNA-142-5p facilitates the pathogenesis of ulcerative colitis by regulating SOCS1[J]. Int J Clin Exp Pathol, 2018, 11(12): 5735-5744.
[7] 吴开春, 梁洁, 冉志华, 等. 炎症性肠病诊断与治疗的共识意见(2018 年? 北京)[J]. 中国实用内科杂志,2018, 38(9):796-813. WU Kaichun, LIANG Jie, RAN Zhihua, et al. Chinese consensus on diagnosis and treatment of inflammatory bowel disease (Beijing, 2018)[J]. Chinese Journal of Practical Internal Medicine, 2018, 38(9):796-813.
[8] ZHU Fengqin, QIN Yufen, WANG Yan, et al. Critical roles of RGS16 in the mucosal inflammation of ulcerative colitis[J]. Eur J Gastroenterol Hepatol, 2022, 34(10):993-999.
[9] KAENKUMCHORN T, WAHBEH G. Ulcerative colitis: making the diagnosis[J]. Gastroenterol Clin North Am, 2020, 49(4):655-669.
[10] 陈绪林, 赵艳, 韩骏飞. 溃疡性结肠炎患者血清CC趋化因子配体11 的表达水平及意义[J]. 国际消化病杂志, 2020, 40(5):343-347. CHEN Xulin, ZHAO Yan, HAN Junfei. Expression and significance of serum CC chemokine ligand 11 in patients with ulcerative colitis[J]. International Journal of Digestive Diseases, 2020, 40(5):343-347.
[11] KUAI Xiaoyi, YU Shunying, CUI Xiufang, et al. LncRNA LUCAT1 as a Plasma Biomarker for assessing disease activity in adult patients with crohn’s disease[J].Gastroenterol Res Pract, 2021, 28(9):7357-7364.
[12] CHEN Sian, SHEN Xian. Long noncoding RNAs: functions and mechanisms in colon cancer[J]. Mol Cancer, 2020, 19(1):167.
[13] ZHU Mingyan, XIE Jian. LncRNA MALAT1 promotes ulcerative colitis by upregulating LncRNA ANRIL[J].Dig Dis Sci, 2020, 65(11):3191-3196.
[14] SHEN Xuning, HU Xiu, MAO Jiayan, et al. The long noncoding RNA TUG1 is required for TGF-beta/TWIST1/EMT-mediated metastasis in colorectal cancer cells[J]. Cell Death Dis, 2020, 11(1):65.
[15] LI Ping, CAI Jiaxun, HAN Fei, et al. Expression and significance of miR-654-5p and miR-376b-3p in patients with colon cancer[J]. World J Gastrointest Oncol, 2020, 12(4):492-502.
[16] ZHAO Jie, WANG Honggang, ZHOU Jin, et al. MiR-130a-3p, a preclinical therapeutic target for crohn’s disease[J]. J Crohns Colitis, 2021, 15(4):647-664.
[17] 刘丽, 柳云恩. 溃疡性结肠炎患者血清miR-15 表达水平与炎性反应状态及预后的关系[J]. 国际消化病杂志, 2020, 40(1):41-46. LIU Li, LIU Yunen. Relationship between the expression of serum miR-15 and inflammatory status and prognosis in patients with ulcerative colitis[J].International Journal of Digestive Diseases, 2020, 40(1):41-46.
[18] DUIJVIS N W, MOERLAND P D, KUNNE C, et al. Inhibition of miR-142-5P ameliorates disease in mouse models of experimental colitis[J]. PLoS One, 2017, 12(10): e0185097.
[19] WOHNHAAS C T, SCHMID R, ROLSER M, et al. Fecal micrornas show promise as noninvasive crohn’s disease biomarkers[J]. Crohns Colitis, 2020, 2(1):otaa003.
[20] HAN Jing, LI Yawei, ZHANG Baoilian et al. LncRNA TUG1 regulates ulcerative colitis through miR-142-5p/SOCS1 axis[J]. Microb Pathog, 2020, 143(6):104139.
[21] 张凤, 罗德兰, 钟玉全. 血清微小RNA-155 表达与溃疡性结肠炎患者病情严重程度及复发的关系[J].山东医药, 2021, 61(1):73-76. ZHANG Feng, LUO Delan, ZHONG Yuquan. Relationship between serum microRNA-155 expression and severity and recurrence of ulcerative colitis[J].Shandong Medical Journal, 2021, 61(1):73-76.

相似文献/References:

[1]杨思贤,慕奕彤,牛福玉.粪便S100A12，钙卫蛋白和乳铁蛋白对溃疡性结肠炎患者疾病活动度和黏膜愈合评估价值分析[J].现代检验医学杂志,2022,37(03):172.[doi:10.3969/j.issn.1671-7414.2022.03.036]
　YANG Si-xian,MU Yi-tong,NIU Fu-yu.Evaluation Value of Stool S100A12, Fecal Calprotectin and Lactoferrin for Disease Activity and Mucosal Healing in Patients with Ulcerative Colitis[J].Journal of Modern Laboratory Medicine,2022,37(05):172.[doi:10.3969/j.issn.1671-7414.2022.03.036]
[2]王 飞,祝 靳,赵宝林.溃疡性结肠炎患者血清LncRNA Mirt2 和LncRNA IFNG-AS1 表达水平及与预后相关性研究[J].现代检验医学杂志,2023,38(03):114.[doi:10.3969/j.issn.1671-7414.2023.03.020]
　WANG Fei,ZHU Jin,ZHAO Bao-lin.Study on the Expression Levels of Serum LncRNA Mirt2 and LncRNA IFNGAS1 in Patients with Ulcerative Colitis and Their Correlation with Prognosis[J].Journal of Modern Laboratory Medicine,2023,38(05):114.[doi:10.3969/j.issn.1671-7414.2023.03.020]
[3]王 燕a,胡秀娟a,张 丽a,等.溃疡性结肠炎患者血清Elabela，LRG1水平表达与疾病活动指数的相关性研究[J].现代检验医学杂志,2024,39(01):100.[doi:10.3969/j.issn.1671-7414.2024.01.018]
　WANG Yana,HU Xiujuana,ZHANG Lia,et al.Correlation between the Expression of Serum Elabela, LRG1 Levels and Disease Activity Index in Patients with Ulcerative Colitis[J].Journal of Modern Laboratory Medicine,2024,39(05):100.[doi:10.3969/j.issn.1671-7414.2024.01.018]
[4]沈丹丹,王 鸿.溃疡性结肠炎活动期患者血清TRIM22 和KLF2 水平与病情及临床结局的关系[J].现代检验医学杂志,2024,39(04):143.[doi:10.3969/j.issn.1671-7414.2024.04.026]
　SHEN Dandan,WANG Hong.Relationship among Serum TRIM22 and KLF2 Levels, Disease Condition and Clinical Outcome of Patients with Active Ulcerative Colitis[J].Journal of Modern Laboratory Medicine,2024,39(05):143.[doi:10.3969/j.issn.1671-7414.2024.04.026]

备注/Memo

备注/Memo:
基金项目：海南省卫生健康行业科研项目（编号2102320242A2001）：血清Nesfatin-1 在炎症性肠病中的水平检测及临床意义的研究。
作者简介：关李稳（1985-），男，本科，主治医师，研究方向：炎症性肠病诊治，E-mail：glwen1930@163.com。
通讯作者：阚娜（1982-），女，硕士，主任医师，研究方向：消化道疾病诊治，E-mail：109758857@qq.com。
更新日期/Last Update: 2023-09-15